Accès ouvert
2025
article
OpenAlex
Christopher H. Rhee, Subir Goyal, Y. Liu, Dylan J. Martini et autres
BACKGROUND: Metastatic urothelial carcinoma (mUC) remains highly lethal despite advances in treatment. There is limited data surrounding the efficacy and toxicity of immune checkpoint inhibitors in treating elderly patients due to the high bar of clinical trial participation. The Geriatric 8 (G8) …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Dylan J. Martini, Catherine J. Wu
In early clinical studies, genomics-guided personalized cancer vaccines (PCV) have demonstrated the capabilities of inducing long-term, tumor-specific immune responses across various malignancies, clinical settings, and treatment regimens. Now that PCVs have advanced to large-scale, randomized clinical trials, we are at a pivotal …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Ahmet Yıldırım, Yuan Liu, Angelo Marra, Yujin Choi et autres
512 Background: Non-clear cell renal cell carcinoma (nccRCC) includes several molecularly distinct subtypes of renal carcinoma. Due to their rarity, nccRCC subtypes have been understudied, and treatment options are often adapted from clear cell RCC therapies. Trials investigating immune checkpoint inhibitors (ICIs) …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Ahmet Yıldırım, Mengting Wei, Yuan Liu, Yujin Choi et autres
603 Background: Multiple studies on various cancer types have investigated concomitant statin, aspirin, and metformin use with immune checkpoint inhibitors. While some found improved OS and PFS, others reported no significant effect. In RCC, a retrospective study linked statins with improved OS …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Katherine B. Case, Dylan J. Martini, Melad Dababneh, Samuel Bidot et autres
OBJECTIVES: Urothelial carcinomas (UCs) encompass a heterogeneous group of tumors. Several histopathologic features are associated with poor clinical outcomes and limited treatment options. With new rising therapeutic modalities, we aimed to determine the pattern of expression of Trop-2 and ephrin B2 in …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Dylan J. Martini, Katherine B. Case, Derrik Gratz, Kathryn L. Pellegrini et autres
BACKGROUND: Bladder cancer with divergent differentiation (BCDD) comprises a heterogenous group of tumors with a poor prognosis, and differential expression of nectin-4 and programmed death ligand-1 (PD-L1) has been reported in BCDD. Importantly, nectin-4 expression in bladder cancer is associated with response …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Yujin Choi, Rohit Vivek Goswamy, Mengting Wei, Yuan Liu et autres
e16542 Background: Current first-line therapy for aRCC involves ICIs, often administered with another ICI or tyrosine-kinase inhibitors (TKIs). While there has been some literature on the association between gender and clinical outcomes in patients with aRCC, some results are contradictory and thus …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Rohit Vivek Goswamy, Ahmet Yıldırım, Yujin Choi, Mengting Wei et autres
e16535 Background: Recent data have reported on obesity as a probable protective factor in metastatic RCC (mRCC). Current knowledge and expanding data suggests a higher BMI (overweight and obese patients) have better survival outcomes. We hypothesize that mRCC patients studied at our …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Rohit Vivek Goswamy, Ahmet Yıldırım, Mengting Wei, Yuan Liu et autres
e16527 Background: Recent data have reported CD8 T cell infiltration into the intratumoral environment has been associated with favorable clinical outcomes in those patients who had tumor resection months/years prior to metastatic diagnosis and systemic therapy. We hypothesize that mRCC patients studied …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Yujin Choi, Ahmet Yıldırım, Mengting Wei, Yuan Liu et autres
e16539 Background: Race has been regarded to be associated with clinical outcome of aRCC patients undergoing therapy with ICIs, but larger data is still limited. Here, we evaluated race and clinical outcome in aRCC patients treated with ICI. Methods: A retrospective analysis …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Christopher H. Rhee, Subir Goyal, Yuan Liu, Dylan J. Martini et autres
e16575 Background: Checkpoint inhibitors (CPI) blocking PD-1 or PD-L1 are a mainstay in the treatment of metastatic urothelial cell carcinoma (mUC). Due to the high bar for clinical trial participation, older patients are underrepresented in trials resulting in FDA-approved therapies that are …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Ahmet Yıldırım, Mengting Wei, Yuan Liu, Rohit Vivek Goswamy et autres
4556 Background: Immune Checkpoint Inhibitors (ICIs) have been the mainstay treatment for advanced renal cell carcinoma (aRCC). However, irAEs are still a challenge in clinical practice. We tested irAEs with inflammatory biomarkers and their association with clinical outcomes. Methods: A retrospective analysis …
us
(code pays fourni par la source)